First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally

NCT Number	NCT07560865
Lead Sponsor	Masonic Cancer Center, University of Minnesota Collaborators: Fate Therapeutics
Conditions	Astrocytoma, Glioblastoma, Progressive Disease
Enrollment	9 participants
Start Date	2026-04-23
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-01